Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3372432rdf:typepubmed:Citationlld:pubmed
pubmed-article:3372432lifeskim:mentionsumls-concept:C0015259lld:lifeskim
pubmed-article:3372432lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3372432lifeskim:mentionsumls-concept:C0009830lld:lifeskim
pubmed-article:3372432lifeskim:mentionsumls-concept:C0439590lld:lifeskim
pubmed-article:3372432pubmed:issue2lld:pubmed
pubmed-article:3372432pubmed:dateCreated1988-6-27lld:pubmed
pubmed-article:3372432pubmed:abstractTextThe effect of beta-adrenergic blockade on the drift in O2 consumption (VO2 drift) typically observed during prolonged constant-rate exercise was studied in 14 healthy males in moderate heat at 40% of maximal O2 consumption (VO2max). After an initial maximum cycle ergometer test to determine the subjects' control VO2max, subjects were administered each of three medications: placebo, atenolol (100 mg once daily), and propranolol (80 mg twice daily), in a randomized double-blind fashion. Each medication period was 5 days in length and was followed by a 4-day washout period. On the 3rd day of each medication period, subjects performed a maximal cycle ergometer test. On the final day of each medication period, subjects exercised at 40% of their control VO2max for 90 min on a cycle ergometer in a warm (31.7 +/- 0.3 degrees C) moderately humid (44.7 +/- 4.7%) environment. beta-Blockade caused significant (P less than 0.05) reductions in VO2max, maximal minute ventilation (VEmax), maximal heart rate (HRmax), and maximal exercise time. Significantly greater decreases in VO2max, VEmax, and HRmax were associated with the propranolol compared with the atenolol treatment. During the 90-min submaximal rides, beta-blockade significantly reduced heart rate. Substantially lower values for O2 consumption (VO2) and minute ventilation (VE) were observed with propranolol compared with atenolol or placebo. Furthermore, VO2 drift and HR drift were observed under atenolol and placebo conditions but not with propranolol. Respiratory exchange ratio decreased significantly over time during the placebo and atenolol trials but did not change during the propranolol trial.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:3372432pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3372432pubmed:languageenglld:pubmed
pubmed-article:3372432pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3372432pubmed:citationSubsetIMlld:pubmed
pubmed-article:3372432pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3372432pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3372432pubmed:statusMEDLINElld:pubmed
pubmed-article:3372432pubmed:monthFeblld:pubmed
pubmed-article:3372432pubmed:issn8750-7587lld:pubmed
pubmed-article:3372432pubmed:authorpubmed-author:WilmoreJ HJHlld:pubmed
pubmed-article:3372432pubmed:authorpubmed-author:JoynerM JMJlld:pubmed
pubmed-article:3372432pubmed:authorpubmed-author:FreundB JBJlld:pubmed
pubmed-article:3372432pubmed:authorpubmed-author:JilkaS MSMlld:pubmed
pubmed-article:3372432pubmed:authorpubmed-author:KalisJ KJKlld:pubmed
pubmed-article:3372432pubmed:authorpubmed-author:NittoloJJlld:pubmed
pubmed-article:3372432pubmed:issnTypePrintlld:pubmed
pubmed-article:3372432pubmed:volume64lld:pubmed
pubmed-article:3372432pubmed:ownerNLMlld:pubmed
pubmed-article:3372432pubmed:authorsCompleteYlld:pubmed
pubmed-article:3372432pubmed:pagination753-8lld:pubmed
pubmed-article:3372432pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:meshHeadingpubmed-meshheading:3372432-...lld:pubmed
pubmed-article:3372432pubmed:year1988lld:pubmed
pubmed-article:3372432pubmed:articleTitleEffect of beta-blockade on the drift in O2 consumption during prolonged exercise.lld:pubmed
pubmed-article:3372432pubmed:affiliationDepartment of Exercise and Sport Sciences, University of Arizona, Tucson 85721.lld:pubmed
pubmed-article:3372432pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3372432pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3372432pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3372432pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:3372432pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed